| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma
|
Lam, Wei-Sen
|
|
|
140 |
C |
p. 87-92
|
artikel
|
| 2 |
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients
|
Reale, Maria Lucia
|
|
|
140 |
C |
p. 71-79
|
artikel
|
| 3 |
Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases
|
Wu, Haijun
|
|
|
140 |
C |
p. 80-86
|
artikel
|
| 4 |
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma
|
Gibert, Joan
|
|
|
140 |
C |
p. 42-45
|
artikel
|
| 5 |
Contents
|
|
|
|
140 |
C |
p. v-vi
|
artikel
|
| 6 |
Editorial Board
|
|
|
|
140 |
C |
p. iii
|
artikel
|
| 7 |
Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry
|
Smit, H.J.M.
|
|
|
140 |
C |
p. 107-112
|
artikel
|
| 8 |
First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations
|
Shoji, Satoshi
|
|
|
140 |
C |
p. 113-115
|
artikel
|
| 9 |
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer
|
Pruis, M.A.
|
|
|
140 |
C |
p. 46-54
|
artikel
|
| 10 |
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program
|
Baldini, Editta
|
|
|
140 |
C |
p. 59-64
|
artikel
|
| 11 |
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis
|
Giaj Levra, Matteo
|
|
|
140 |
C |
p. 99-106
|
artikel
|
| 12 |
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
|
Beau-Faller, Michèle
|
|
|
140 |
C |
p. 19-26
|
artikel
|
| 13 |
Is the English Cancer Patient Experience Survey representative? A comparative analysis with the National Lung Cancer Audit
|
Nartey, Yvonne
|
|
|
140 |
C |
p. 27-34
|
artikel
|
| 14 |
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas
|
Sands, Jacob M.
|
|
|
140 |
C |
p. 35-41
|
artikel
|
| 15 |
Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing
|
Toffart, Anne-Claire
|
|
|
140 |
C |
p. 93-98
|
artikel
|
| 16 |
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan
|
Morita, Ryo
|
|
|
140 |
C |
p. 8-18
|
artikel
|
| 17 |
Real-world guideline-based treatment of lung cancer improves short- and long-term outcomes and resection rate: A population-based study
|
Helminen, Olli
|
|
|
140 |
C |
p. 1-7
|
artikel
|
| 18 |
Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment
|
Edahiro, Ryuya
|
|
|
140 |
C |
p. 116-117
|
artikel
|
| 19 |
Survival disparities following surgery among patients with different histological types of non-small cell lung cancer
|
Grosu, Horiana B.
|
|
|
140 |
C |
p. 55-58
|
artikel
|
| 20 |
Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI
|
Tang, Yi
|
|
|
140 |
C |
p. 65-70
|
artikel
|
| 21 |
Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib
|
Wang, Fenfang
|
|
|
140 |
C |
p. 118-120
|
artikel
|
Tijdschrift beschrijving